$PPCBOct 16, 2026, 8:36 AM ETAI processed
Propanc says preclinical PRP remodels chemo‑resistant pancreatic cells, supports Phase 1b in Q1 2027
AI Summary
Propanc (PPCB) released preclinical data showing its lead proenzyme formulation PRP reprograms chemotherapy‑resistant pancreatic cancer cells and that PRP pre‑treatment increased subsequent sensitivity to chemotherapy, results the company says support a planned First‑In‑Human Phase 1b study in Q1 2027. In vitro models reported PRP cut proliferation ~50% (54% in resistant cells), reduced clonogenic survival, migration and invasion, reversed EMT markers (E‑cadherin up, vimentin/snail down) and showed stronger effects when combined with a TGF‑β inhibitor, though responses varied by model and no in vivo or clinical efficacy data were presented.
Positives
- Preclinical data show PRP can remodel chemoresistant cellular states and increase vulnerability to subsequent chemotherapy in sequential PRP → chemo experiments
- PRP monotherapy reduced proliferation ~50% in wild‑type and 54% in chemoresistant cells and suppressed long‑term clonogenic survival
- PRP reversed EMT markers and markedly reduced migration/invasion; combination with a TGF‑β inhibitor amplified anti‑invasive and pro‑apoptotic effects
Negatives
- Data are preclinical and in vitro only — no animal or human efficacy data presented
- Response magnitude and molecular changes differed between tumor models, indicating heterogeneity of effect
- Planned Phase 1b is only announced (Q1 2027); clinical benefit in patients remains unproven